Chowdhury, Namara MariamKevin, Kyazze2025-05-222025-05-2220252025-02ID 21146063http://hdl.handle.net/10361/25975Cataloged from PDF version of thesis.Includes bibliographical references (pages 25-28).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2025.Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. Breast cancer originates from the breast tissue especially from the inner lining of milk ducts or the lobules that supply the ducts with milk. The MYC gene plays a central role in the proliferation and malignant transformation of animal and human cells. Most of the human malignancies have been reported to have amplification or over expression of this gene. Use of MESH terms like MYC and Breast cancer were used in the selection of studies which fit the selection criteria for inclusion. It was found out that drug molecules like OMO-103, MYCi975, 3’UTRMYC-18 with OMO-103 showing a 49% reduction in tumor volume reduction as well as other molecular targets like Prox1 in combination with existing chemotherapy have showed promising prognosis in the treatment of breast cancer by reducing the overexpression and amplification of MYC gene and its downstream processes.28 pagesenBRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.MYC oncogeneBreast cancerMYC amplificationMYC overexpressionHazard Ratio (HR)Tumor volumeBrest cancer--TreatmentThesis